Literature DB >> 10395196

Adrenoceptor genes in human obesity.

P Arner1, J Hoffstedt.   

Abstract

The genes causing obesity in rodent models have been characterized, but do not seem to be important for human obesity. Recently the putative association between obesity and polymorphism in human beta-adrenergic receptor genes have been studied intensely in the light of the important role of these receptors in the regulation of energy mobilization and utilization. A polymorphism (Trp64Arg) in the beta3-adrenergic receptor gene is associated with obesity (relative risk approximately 2) in some but not all investigations on Caucasian and Japanese populations. When expressed in artificial cell systems, the polymorphism is associated with alterations of the beta -adrenoceptor. The genetic allele variance influences also the native receptor function when measured in isolated human fat cells. The human beta2-adrenoceptor gene shows a high degree of polymorphism. The role of beta2-receptor gene polymorphism for obesity has so far only been investigaed in women. A Gln27Glu variant is markedly associated with obesity with a relative risk for obesity of approximately 7 and odds ratio of approximately 10. Women who are homozygous for 27Glu have approximately 20 kg higher fat mass than controls. Thus, polymorphism in genes coding for different beta-adrenoceptor subtypes may be important for the development of human obesity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395196     DOI: 10.1046/j.1365-2796.1999.00495.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  24 in total

Review 1.  Genetic polymorphisms of adrenergic receptors.

Authors:  E M Garland; I Biaggioni
Journal:  Clin Auton Res       Date:  2001-04       Impact factor: 4.435

Review 2.  Drug treatment of obesity: from past failures to future successes?

Authors:  P Collins; G Williams
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

Review 3.  Beta-adrenoceptor polymorphisms.

Authors:  K Leineweber; R Büscher; H Bruck; O-E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-28       Impact factor: 3.000

Review 4.  Pharmacogenetics of antipsychotic-induced weight gain.

Authors:  Christoph U Correll; Anil K Malhotra
Journal:  Psychopharmacology (Berl)       Date:  2004-07-08       Impact factor: 4.530

5.  ADRB2 gene variants, dual-energy x-ray absorptiometry body composition, and hypertension in Tobago men of African descent.

Authors:  Tracey Samantha Beason; Clareann H Bunker; Joseph M Zmuda; John W Wilson; Alan L Patrick; Victor W Wheeler; Joel L Weissfeld
Journal:  Metabolism       Date:  2010-08-19       Impact factor: 8.694

6.  β(3) Receptors: Role in Cardiometabolic Disorders.

Authors:  Shraddha V Bhadada; Bhoomika M Patel; Anita A Mehta; Ramesh K Goyal
Journal:  Ther Adv Endocrinol Metab       Date:  2011-04       Impact factor: 3.565

7.  A maximal effort trial in obese women carrying the beta2-adrenoceptor Gln27Glu polymorphism.

Authors:  T Macho-Azcárate; J Calabuig; A Martí; J A Martínez
Journal:  J Physiol Biochem       Date:  2002-06       Impact factor: 4.158

8.  Diverse evolutionary histories for beta-adrenoreceptor genes in humans.

Authors:  Rachele Cagliani; Matteo Fumagalli; Uberto Pozzoli; Stefania Riva; Giacomo P Comi; Federica Torri; Fabio Macciardi; Nereo Bresolin; Manuela Sironi
Journal:  Am J Hum Genet       Date:  2009-07-02       Impact factor: 11.025

9.  A simple and rapid genotyping assay for simultaneous detection of two ADRB2 allelic variants using fluorescence resonance energy transfer probes and melting curve analysis.

Authors:  M Fernanda Sábato; Anne-Marie Irani; Bonny L Bukaveckas; Lawrence B Schwartz; David S Wilkinson; Andrea Ferreira-Gonzalez
Journal:  J Mol Diagn       Date:  2008-05       Impact factor: 5.568

Review 10.  What do we know and not know about mirabegron, a novel β3 agonist, in the treatment of overactive bladder?

Authors:  Romain Caremel; Oleg Loutochin; Jacques Corcos
Journal:  Int Urogynecol J       Date:  2013-08-07       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.